THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Patent applications |
Patent application number | Title | Published |
20160136297 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 05-19-2016 |
20160130334 | NOTCH INHIBITION IN THE TREATMENT AND PREVENTION OF OBESITY - The present invention is directed to methods of treating or preventing obesity by administering agents that inhibit the NOTCH signaling pathway. Antibodies that inhibit the binding of Delta like 4 ligand (Dll4) to NOTCH receptors may be used for this purpose. | 05-12-2016 |
20160129030 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS - Embodiments disclosed herein provide compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC). Such methods and compositions comprise at least one compound selected from the group consisting of nateglinide, Z-L-Phe chloromethyl ketone, clemastine fumarate, supercinnamaldehyde, practolol, fluvastatin Na, sulindac, BIO, amorolfine, spectinomucin, sibutramine HCl, nelfinavir mesylate, moroxydine HCl, nicotine ditartrate, trequinsin, meglumine, tizanidine HCl, CGP-74514A hydrochloride, tioconazole, TOVOK™ (afatinib), or kasugamycin. | 05-12-2016 |
20160122394 | FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOF - The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function. | 05-05-2016 |
20160120945 | Thymic Regeneration - Methods for regenerating thymic tissues, e.g., for the treatment of subjects who have thymic insufficiency, i.e., whose thymic tissues are absent or atrophied due to illness, age, or injury, by administration of growth differentiation factor 11 (GDF11). | 05-05-2016 |
20160106782 | WOUND HEALING AND TISSUE ENGINEERING - The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds. | 04-21-2016 |
20160067272 | METHODS FOR TREATING IMMUNE DISEASES - Provided herein are methods for treating or preventing an immune disease in a subject by administering a composition comprising a therapeutically effective amount of NAD+. Also provided herein are methods and assays for diagnosing an immune disease in a subject by measuring the level of NAD+ in a biological sample obtained from the subject. | 03-10-2016 |
20160058792 | METHODS AND COMPOSITIONS OF TREATING AUTOIMMUNE DISEASES - Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes. | 03-03-2016 |
20160022729 | Compounds to Modulate Intestinal Absorption of Nutrients - This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity. | 01-28-2016 |
20160022706 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS - Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age. | 01-28-2016 |
20160017007 | VIBRO-BASED DELIVERY SYSTEM AND IMMUNE SUPPRESSION - Embodiments described are immunosuppressant therapeutics and compositions comprising a Vop protein derived from | 01-21-2016 |
20150355185 | USING GALECTIN-BINDING CARBOHYDRATES AS PREDICTORS OF MELANOMA PROGRESSION AND METASTASIS - Disclosed herein are assays and methods to determine tumor malignancy, for example, in melanoma or ovarian carcinoma, by determining the expression level of Gal-1 ligands. Also provided are methods to assess the metastatic potential of a tumor. | 12-10-2015 |
20150343023 | METHODS FOR CARDIOPROTECTION AND CARDIOREGENERATION WITH DIMERS OF EGF FAMILY LIGANDS - The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue. | 12-03-2015 |
20150338425 | TREATMENT AND PROGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS - Embodiments disclosed herein relate to treatment methods, diagnosis methods, drug efficacy evaluation methods and prognosis evaluation methods of lymphangioleiomyomatosis (LAM) and a disease associated with a mutation in a tuberous sclerosis complex (TSC) gene. The methods comprising analyses of the levels of lysophosphatidylcholine (LPC) in a biological sample of a subject, or comprising analyses of images of the location and signal intensity of isotope-labeled choline in the subject. | 11-26-2015 |
20150337380 | Compositions and Methods for Diagnosing and Assessing Inflammatory Myopathies - The present invention is directed to assay methods for inflammatory myopathies and microarray plates that can be used in carrying out these assays. | 11-26-2015 |
20150337319 | TETRACYCLINE-REGULATED GENE EXPRESSION IN HSV-1 VECTORS - The present invention is directed to HSV-1 vectors which rely on the tetracycline repressor and operator as a means for regulating expression. The vectors utilize VP-16 responsive promoters of HSV to control expression of the tetracycline repressor. The vectors are of particular interest as vehicles for recombinantly expressing genes in vivo. | 11-26-2015 |
20150330989 | METHOD AND SYSTEM FOR DIAGNOSING AND TREATING PREECLAMPSIA - Described herein are methods, systems and kits of the diagnosis of preeclampsia and HELLP syndrome, as well as the selection of a preeclampsia or HELLP syndrome treatment. These are based, at least in part, on the finding that proximal tubule injury, as measured by urinary KIM-1, is increased in severe preeclampsia and correlates with complement activation. The detection of complement proteins correlate with kidney injury in severe preeclampsia and/or HELLP syndrome and terminal complement blockage is a therapeutic approach taken as described in various embodiments of the present invention. | 11-19-2015 |
20150329620 | POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to | 11-19-2015 |
20150328193 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS - Embodiments disclosed herein provide combinatorial compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis complex (TSC) using combination drug therapy comprising rapamycin and at least one of SCH-202676 hydrobromide, danusertib (PHA-739358), AZ-960, SB-590885, Thimerosal, ionomycin, U-73343, PAF C16, BX912, and Chlorambucil. In addition, methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, or treating and/or management of tuberous sclerosis complex (TSC) using other known drugs are provided. | 11-19-2015 |
20150315577 | A METHOD FOR INHIBITING CALCIFICATION OF A MACROPHAGE-DERIVED MATRIX VESICLE - The invention relates to methods for decreasing, inhibiting, preventing, or reducing matrix vesicle induced calcification by inhibiting the amount or formation of a complex comprising phosphatidylserine (PS), annexin II, annexin V or VI, and S100A9 or S100A12 in a macrophage. | 11-05-2015 |
20150301049 | METHOD FOR DIAGNOSING AND TREATING KIDNEY INJURY OR DISEASE - The protein kinase C and casein kinase 2 substrate in neurons (Pacsin) is a subfamily of membrane-binding proteins, participates in vesicle trafficking and cytoskeleton organization. Pacsin 2 expression is significantly upregulated during the repair phase of post ischemia-reperfusion injured (IRI) kidneys, especially on the apical brush border of proximal tubules, which experienced massive damage. Described herein are methods, kits and systems for the diagnosis, selection and treatment of kidney injury and kidney diseases. | 10-22-2015 |
20150293114 | DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS AND RELATED CONDITIONS - The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders. | 10-15-2015 |
20150291963 | SORTILIN 1 IS A NOVEL INDUCER OF VASCULAR CALCIFICATION - The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1. | 10-15-2015 |
20150285807 | SYSTEM AND METHOD FOR DETECTING CANCER - Disclosed herein are methods of detecting malignancy in a tumor of a subject comprising measuring the amount of 5-hmC in a tumor sample and comparing to a control to thereby detect a level of reduction of 5-hmC in the tumor, wherein the tumor is characterized as malignant if a threshold level of reduction is detected. The tumor may be a solid tumor such as a melanocytic lesion. Also disclosed are methods of determining the prognosis of a subject with a tumor by determination of the amount of 5-hmC in the tumor. Methods for treatment of a tumor with reduced 5-hmC are also disclosed. | 10-08-2015 |
20150273056 | ENHANCEMENT OF THE IMMUNE RESPONSE - The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance. | 10-01-2015 |
20150266955 | DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis. | 09-24-2015 |
20150225457 | MODULATION OF THE IMMUNE RESPONSE - Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation. | 08-13-2015 |
20150212072 | FUNCTIONAL ASSAY FOR CANCER RECURRENCE AND MALIGNANT POTENTIAL - Embodiments herein provides an in vitro co-culture system comprising a population of cancer responder cells and a population of non-tumor cells wherein the cancer responder cells can convert to a malignant state and exhibit hallmark malignant phenotype when the cells are placed in a tumor supportive environment. The system is useful for prognosis evaluation of cancer recurrence, malignancy development, cancer drug screening and surveillance for resistance to cancer drug therapy. | 07-30-2015 |
20150210727 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS - Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants. | 07-30-2015 |
20150209509 | METHODS AND DEVICES FOR INSERTING A NEEDLE - An apparatus provides targeted placement of openings for infusing fluids into a body. The apparatus provides a driving force to a penetrating medical device, such as a needle, when the apparatus tip encounters material of high resistance. When the apparatus tip encounters a low resistance material, no further driving force is applied to the apparatus due to contraction of an element made of interlaced flexible elements. A multi-opening needle is provided in some embodiments wherein placement of one of the openings in a target region with a relatively lower external pressure allows pressurized fluid to exit the needle while openings remaining in higher pressure, non-target regions do not release substantial amounts of the fluid. | 07-30-2015 |
20150203563 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION - The technology described herein is directed to agents that reduce the level of oxidant-modified ET-B Cys405, Cys403, or Cys402 and the identification and use of such agents for, e.g. to treat hypertension. | 07-23-2015 |
20150191536 | Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 - The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. | 07-09-2015 |
20150174138 | DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY - The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor. | 06-25-2015 |
20150153360 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 06-04-2015 |
20150119557 | IN VITRO CULTURE CONDITIONS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA - We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor. | 04-30-2015 |
20150112261 | METHODS AND DEVICES FOR SENSING TISSUES AND TISSUE COMPARTMENTS - An apparatus provides feedback regarding the material in which tip of the apparatus is located as the tip is advanced into matter of varying resistances. The apparatus responds to a change in pressure, force, or other parameter such that when the tip reaches matter of a certain resistance, a change in the parameter is sensed. The apparatus provides a driving force to a penetrating medical device, such as a needle, when the apparatus tip encounters material of high resistance. When the apparatus tip encounters a low resistance material, no further driving force is applied to the apparatus. An inner core may be advanced into the low resistance material for deployment of a gas or a liquid as desired. | 04-23-2015 |
20150064174 | NEUTRALIZING ANTIBODY FOR EPSTEIN BARR VIRUS-ASSOCIATED DISEASE - Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody. | 03-05-2015 |
20150050732 | SELECTIVE DIFFERENTIATION, IDENTIFICATION, AND MODULATION OF HUMAN TH17 CELLS - The embodiments provide for the modulation of both the differentiation and activity of human Th17 cells. More specifically, human Th17 cell differentiation can modulated by TGF-β and IL-21, and their agonists and antagonists. Function of Th17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of Th17 cells. More specifically, human Th17 cells specifically upregulate BLT1 and podoplanin. | 02-19-2015 |
20150044230 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 02-12-2015 |
20150044229 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 02-12-2015 |
20150031742 | TREATMENT OF UTERINE LEIOMYOMATA - Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided. | 01-29-2015 |
20150025553 | RIGHT VENTRICULAR PAPILLARY APPROXIMATION - A device for treating tricuspid regurgitation includes a shaft and a first fixation mechanism disposed on a distal end of the shaft. The first fixation mechanism is configured to anchor the device to a first cardiac tissue. The device includes a second fixation mechanism disposed on a proximal end of the shaft. The second fixation mechanism is configured to anchor the device to a second cardiac tissue. The device includes an approximation mechanism connecting the first fixation mechanism and the second fixation mechanism, wherein the approximation mechanism causes the second fixation mechanism to move along the shaft toward the first fixation mechanism to approximate the first cardiac tissue and the second cardiac tissue. | 01-22-2015 |
20150025257 | DOCOSAHEXAENOYL ETHANOLAMIDES - The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 01-22-2015 |
20150023875 | System for Targeted Delivery of Therapeutic Agents - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 01-22-2015 |
20150011603 | ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS - The invention is directed to compounds according to formula (I): where R | 01-08-2015 |
20140378388 | TREATMENT OF UTERINE LEIOMYOMATA - Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided. | 12-25-2014 |
20140370526 | DETECTING INCLUSION BODY MYOSITIS - Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kDa) protein or ˜43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1A protein (NT5C1A), or a cytosolic 5′-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies. | 12-18-2014 |
20140348896 | Hydrophobic Tissue Adhesives - Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response. | 11-27-2014 |
20140348842 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 11-27-2014 |
20140329834 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses - The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses. | 11-06-2014 |
20140328841 | ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY - Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer. | 11-06-2014 |
20140322199 | METHODS OF TREATING CARDIOVASCULAR AND METABOLIC DISEASES - The technology described herein is directed to methods of treating cardiovascular and metabolic disorders. | 10-30-2014 |
20140314811 | HERPES SIMPLEX VIRUS VACCINES - The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes. | 10-23-2014 |
20140303251 | Methods Of Treating Acute Kidney Injury With Retinoic Acid - The present invention provides, in one embodiment, a method of inhibiting apoptosis in kidney epithelial cells after acute injury by modulating/inhibiting Nur77 induction/expression or function/activity in the cells. The invention further provides a method of preventing or treating an acute kidney injury in a subject in need thereof, comprising administering to the subject an effective amount of a retinoic acid or retinoic acid derivative, and a method of preserving a kidney for transplant, comprising contacting the kidney with a solution that comprises a retinoic acid or a, retinoic acid derivative. | 10-09-2014 |
20140302031 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 10-09-2014 |
20140296327 | DIAGNOSIS AND TREATMENT OF MESOTHELIOMA - This disclosure provides methods for surveillance, early detection and diagnosis, subtype classification, prediction of recurrence, prognosis and therapy of malignant mesothelioma based on profiles of indicator mutations in disclosed genes. | 10-02-2014 |
20140296152 | Stem Cell Derived Factors for Treating Pathologic Conditions - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions. | 10-02-2014 |
20140294993 | METHOD FOR TREATMENT OF MESOTHELIOMA - The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment choices. Furthermore, mesothelioma can be treated by modulating RERG activity, for example, with treatment with estrogen or estrogen-like agents. | 10-02-2014 |
20140255420 | Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders - The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes. | 09-11-2014 |
20140243285 | LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USE THEREOF - The invention provides compositions comprising lipid-conjugated forms of capsular polysaccharide A (PSA) from | 08-28-2014 |
20140242094 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 08-28-2014 |
20140235697 | MICRORNAS IN NEURODEGENERATIVE DISORDERS - The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the rate of disease progression in a subject having a neurodegenerative disorder, selecting a subject for treatment of a neurodegenerative disorder, selecting a subject for participation in a clinical study, and determining the efficacy of treatment of a neurodegenerative disorder. These methods include determining the level of one or more microRNAs and/or one or more inflammatory markers in a monocyte (e.g., a CD14 | 08-21-2014 |
20140206757 | TREATMENT OF CANCER - This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2. | 07-24-2014 |
20140206624 | TREATMENT OF LEUKEMIA - Compositions and methods for the treatment of leukemia by inhibiting FOXO signaling are described. | 07-24-2014 |
20140199284 | STRUCTURAL MUTATIONS IN TITIN CAUSE DILATED CARDIOMYOPATHY - Provided herein are diagnostic markers and methods for identifying a subject having an increased susceptibility for developing or having dilated cardiomyopathy. The method comprises determining if the subject has a mutation in the TTN nucleic as acid or titin polypeptide. Further provided herein are methods of treating subjects having or at risk of having dilated cardiomyopathy. | 07-17-2014 |
20140194340 | DIAGNOSING, MONITORING AND TREATING INFLAMMATION - The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems. | 07-10-2014 |
20140186295 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9 expression in the subject (e.g. administration of TH9 cells that express IL-9, or administration of an inhibitor of ROR). | 07-03-2014 |
20140179630 | USE OF DOCASATRIENES, RESOLVINS, AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 06-26-2014 |
20140178367 | Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2) - Methods of treating inflammatory diseases, e.g., diseases associated with inflammatory CD14+/CD16− monocytes, e.g., amyotrophic lateral sclerosis (ALS), stroke, and glaucoma, using compounds such as small molecules and antibodies that target CCR2 or CCL2. | 06-26-2014 |
20140171621 | Galectin-Immunoglobulin Chimeric Molecules - Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers. | 06-19-2014 |
20140170749 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CF34, CF49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated stem cells, are also provided. | 06-19-2014 |
20140162947 | Kruppel-like Factor 10 (KLF10) as a Biomarker of Endothelial Progenitor Cell Dysfunction - The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis. | 06-12-2014 |
20140155732 | SYSTEMS AND METHODS FOR PORTABLE MAGNETIC RESONANCE MEASUREMENTS OF LUNG PROPERTIES - A portable magnetic resonance (MR) system for quantitatively measuring properties of a subject's lungs, such as regional ventilation and lung density, is provided. The portable MR system includes a magnet, radio frequency (RF) coil assembly, and spectrometer system. The magnet can be positioned near the subject's chest. The magnetic field of the magnet substantially homogeneous in a region-of-interest located at a distance from the surface of the magnet that localizes the region-of-interest in the subject's lung. The RF coil assembly includes one or more RF coils that are sized to be positioned near the subject's chest, and receives MR signals from the region-of-interest. The spectrometer system controls the RF coil assembly and computes from the acquired MR signals, a quantitative metric indicative of a characteristic of the subject's lung in the region-of-interest. An active noise cancellation system is provided so RF shielding of the portable MR system is not required. | 06-05-2014 |
20140148846 | Adhesive Articles Containing a Combination of Surface Micropatterning and Reactive Chemistry and Methods of Making and Using Thereof - Adhesive articles containing microtopography, such as microprotrusions, and a coating of adhesive glue, such an adhesive having known toxicity and/or tissue reactive functional groups are described herein. The articles described herein contain a substrate, a plurality of microfeatures, and an adhesive, such as an adhesive glue. The articles described herein exhibit a 90° pull off adhesion of at least about 1.5 N/cm | 05-29-2014 |
20140135396 | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide - The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide. | 05-15-2014 |
20140134249 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 05-15-2014 |
20140128437 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS - The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role. | 05-08-2014 |
20140127690 | Mutation Signatures for Predicting the Survivability of Myelodysplastic Syndrome Subjects - Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects. | 05-08-2014 |
20140127301 | Adjuvant Incorporation in Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 05-08-2014 |
20140127214 | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF - The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders. | 05-08-2014 |
20140121262 | Methods of Using microRNA-26a to Promote Angiogenesis - Methods for promoting angiogenesis, and for diagnosing the presence or risk of developing disorders associated with impaired angiogenesis or blood flow to a tissue in the body, using microRNA-26a (miR-26a). | 05-01-2014 |
20140099629 | Platelet Additive Solution Having a beta-Galactosidase Inhibitor - The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof. | 04-10-2014 |
20140099331 | ZWITTERIONIC IMMUNOMODULATORS FOR THE TEATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo. | 04-10-2014 |
20140081415 | MICROVASCULAR ANASTOMOTIC COUPLER AND METHODS OF USING SAME - Disclosed herein are devices and methods for fast and simple generation of an anastomosis. In certain embodiments, the devices and methods involve the deployment of self-expanding stents without the use of a catheter. The devices and methods disclosed herein further utilize a sheath that allows an operator to deploy the stent without the use of an inter-lumen device. | 03-20-2014 |
20140079776 | Nanostructures for Drug Delivery - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor. | 03-20-2014 |
20140079631 | ANTI-INFLAMMATORY PARTICLES - Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain. | 03-20-2014 |
20140066325 | Protein Biomarkers for the Diagnosis of Prostate Cancer - The invention is directed to tumor associated markers (TAMs) and autoantibody biomarkers that can be used diagnostically. It also includes methods for detection of the markers and compositions that can be used in carrying out assays | 03-06-2014 |
20140037736 | Targeting of Antigen Presenting Cells With Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 02-06-2014 |
20140024623 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT - The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid. | 01-23-2014 |
20140024595 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 01-23-2014 |
20130344092 | Methods of Using Anti-Thymocyte Globulin and Related Agents - Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-β are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases. | 12-26-2013 |
20130344063 | Diagnosing and Monitoring CNS Malignancies Using MicroRNA - The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity. | 12-26-2013 |
20130336993 | Modulation of the Immune Response - Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3. | 12-19-2013 |
20130336958 | NOTCH Inhibition In The Treatment Of Cardiovascular Disease - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 12-19-2013 |
20130336934 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 12-19-2013 |
20130331792 | DEVICE AND USES THEREOF - The present disclosure provides devices and uses thereof. A devices disclosed herein comprises one or more tips, wherein the one or more tips are designed and constructed to initiate penetration by the device; and one or more protrusions in a region adjacent to each tip. In some embodiments, one or more protrusions can be constructed and arranged so that the required penetration force is reduced as compared with that observed for an otherwise identical device lacking the one or more protrusions. Additionally or alternatively, one or more protrusions can be constructed and arranged such that the required pull-out force is increased as compared with that observed for an otherwise identical device lacking the one or more protrusions. | 12-12-2013 |
20130330715 | ASSAYS AND METHODS TO SEQUENCE MICROBES DIRECTLY FROM IMMUNE COMPLEXES - Provided herein are MiIP-Seq assays and methods for detecting and/or identifying an immune-stimulating microbe in a patient sample. Also provided herein are methods for diagnosing an infectious disease or identifying a previously uncharacterized microbe in a patient sample. The methods and assays described herein are advantageous over existing methods in that they (i) do not require a culture step for microbe expansion, (ii) are not specific for a particular microbe and can be used to identify a previously uncharacterized microbe, and (iii) permits rapid processing due to the lack of a microbe culture step. | 12-12-2013 |
20130317030 | Methods for Diagnosis of Cardiovascular Disease - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 11-28-2013 |
20130315831 | LIPID-POLYMER HYBRID PARTICLES - A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer. | 11-28-2013 |
20130310841 | Femoral Sizing Devices and Procedures for Use in Knee Surgery - The present invention is directed to a femoral sizing device that can be used in knee surgery and to techniques in which this device may prove useful. | 11-21-2013 |
20130310776 | APPLICATION OF POLYMERIC MATERIALS TO SCREENS TO FACILITATE HEMOSTASIS AND WOUND HEALING - This invention relates in general to a method and device for facilitating hemostasis and wound healing. In particular, the invention relates to the device comprising a polymeric material disposed on a scaffold that facilitates hemostasis and wound healing. Specifically, the invention contemplates the use of such scaffolds in conjunction with a negative pressure device. | 11-21-2013 |
20130310384 | Sulfonamide-Containing Compounds - This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase. | 11-21-2013 |
20130309690 | TETRAMERIC ALPHA-SYNUCLEIN AS BIOMARKERS - The present invention provides the surprising finding that alpha-synuclein exists in vivo as a folded tetramer. Provided are various methods and technologies that arise from this finding, including methods and kits for identifying individuals susceptible to or suffering from certain diseases, disorders or conditions associated with stability of alpha-synuclein tetramers, and/or individuals likely (or not) to respond to therapy with agents that alter level and/or stability of alpha-synuclein tetramers. | 11-21-2013 |
20130281312 | METHODS FOR PREDICTING ANTI-CANCER RESPONSE - The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs. | 10-24-2013 |
20130280334 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents - Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described. | 10-24-2013 |
20130253005 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY - Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents. | 09-26-2013 |
20130251664 | 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 09-26-2013 |
20130243806 | POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 09-19-2013 |
20130231362 | Mast Cell Stabilizers in the Treatment of Obesity - The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity. | 09-05-2013 |
20130230455 | USE OF GELSOLIN TO TREAT MULTIPLE SCLEROSIS AND TO DIAGNOSE NEUROLOGIC DISEASES - The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases. | 09-05-2013 |
20130217771 | RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 08-22-2013 |
20130216508 | HUMAN LUNG STEM CELLS AND USES THEREOF - Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases. | 08-22-2013 |
20130209476 | TREATMENT OF INFLAMMATORY DISORDERS - A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist. | 08-15-2013 |
20130197067 | NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES - Provided herein are neuroprotective molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA and at least four contiguous guanosine-containing nucleotides, where the sequence of 25-35 contiguous nucleotides contains a D-loop stem structure, the at least four contiguous guanosine-containing nucleotides are located at the 5′ end of the neuroprotective molecule, and the neuroprotective molecule contains at least one deoxyribonucleotide. Also provided are molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA selected from the group of tRA | 08-01-2013 |
20130196911 | METHODS AND COMPOSITIONS FOR CARDIOPROTECTION AND CARDIOREGENERATION - The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue. | 08-01-2013 |
20130195895 | METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them. | 08-01-2013 |
20130195810 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 08-01-2013 |
20130195809 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 08-01-2013 |
20130183688 | TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses. | 07-18-2013 |
20130183245 | METHODS OF TREATING CEREBRAL AMYLOID ANGIOPATHY - Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant. | 07-18-2013 |
20130177928 | NORMALIZATION OF PLATELET BIOMARKERS - Described herein are methods useful for normalizing any biomarker in platelets. This has application in any method in which one wishes to ascertain or compare the level of a biomarker, e.g., for diagnostic or prognostic methods relating to a biomarker of interest. Using such an approach can permit the assessment of disease status (e.g., angiogenic status) of an individual with less error than an expression value that is not normalized or that is normalized to total protein levels. Also provided are methods for selecting a normalizing protein for normalizing biomarkers in a sample, e.g., a platelet sample. | 07-11-2013 |
20130177549 | Treatment of Synucleinopathies - This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods. | 07-11-2013 |
20130156774 | BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS - Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer. | 06-20-2013 |
20130130348 | Polymers for Functional Particles - A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described. | 05-23-2013 |
20130129790 | Adjuvant Incorporation in Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 05-23-2013 |
20130121966 | Generation of PSA-only producing mutant strain - Provided is an isolated | 05-16-2013 |
20130109630 | METHODS FOR DIAGNOSING AND ASSESSING RISK OF DEVELOPING GLOMERULOSCLEROSIS | 05-02-2013 |
20130102627 | Acridines As Inhibitors Of Haspin And DYRK Kinases - The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity. | 04-25-2013 |
20130102546 | METHODS OF TREATING VASCULAR INFLAMMATORY DISORDERS - Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-R? (NF-R?) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). | 04-25-2013 |
20130092158 | Instrumented Metered-Dose Inhaler and Methods for Predicting Disease Exacerbations - The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made. | 04-18-2013 |
20130040858 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 02-14-2013 |
20130023491 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE - In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK). | 01-24-2013 |
20130017265 | PARTICLES FOR MULTIPLE AGENT DELIVERY - Delivery compositions are provided that include two or more active agents, wherein at least one active agent is conjugated to a polymer. The delivery compositions allow for controlled release of multiple active agents, including active agents with varying solubility, charge, and/or molecular weight. | 01-17-2013 |
20130017218 | LIVE BACTERIAL VACCINE SAFETY - The present invention provides for a method of reducing the reactogenicity of live attentuated bacterial vaccines by deleting at least a portion (e.g., the TLR-5 stimulating domain of a flagellin protein) of at least one of the bacterial genes that encodes a flagellin from the bacterium genome. These vaccines are directed against enteric or non-enteric flagellin-producing bacteria. A particular embodiment provides for a live attenuated cholera vaccine having reduced reactogenicity. | 01-17-2013 |
20130017188 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES - The inventors have made the surprising discovery that SGK1, a serine/threonine kinase previously described as being involved in regulation of cellular sodium homeostasis, has a novel and unexpected function in the differentiation and function of a specific subset of CD4 T cells, the TH17 lineage. Described herein are methods and compositions for modulation of TH17 cell differentiation, proliferation, and/or function that rely upon modulating the activity or expression of SGK1. Such methods and compositions are useful in the treatment of disorders including autoimmune diseases, chronic inflammatory conditions, infectious diseases, and cancer. | 01-17-2013 |
20120331576 | Pathogen Restriction Factors - The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein | 12-27-2012 |
20120321595 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 12-20-2012 |
20120321573 | COMPOSITIONS AND METHODS OF PROPHYLAXIS FOR CONTACT DERMATITIS - The present invention relates to compositions and methods for inhibiting metal exposure to tissues. | 12-20-2012 |
20120315286 | COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 12-13-2012 |
20120315264 | ZWITTERIONIC IMMUNOMODULATORS FOR THE TEATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo. | 12-13-2012 |
20120309955 | ZWITTERIONIC POLYSACCHARIDES FOR PROMOTION OF IMMUNE SYSTEM MATURATION AND HEALTH - Certain zwitterionic polysaccharides, including those naturally expressed by commensal | 12-06-2012 |
20120296070 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 11-22-2012 |
20120295814 | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer - The invention is directed to assays of CA-125 immune complexes that can be used diagnostically. It also includes glass or plastic plates or slides on which the monoclonal antibodies against CA-125 have been immobilized and kits containing these plates or slides. | 11-22-2012 |
20120295809 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 11-22-2012 |
20120288481 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 11-15-2012 |
20120277774 | Method and Apparatus for Vascular Anastomosis - Methods and apparatus can be used for anastomosis, and more specifically, for joining two vascular vessels, e.g., arterial or venous vessels or the like, using a stent. | 11-01-2012 |
20120276084 | Predicting Risk of Age-Related Macular Degeneration - This invention relates to methods for predicting risk of developing age-related macular degeneration (AMD), based on detecting the presence of certain genetic variants on chromosome 16 that are associated with increased incidence of AMD. | 11-01-2012 |
20120264756 | Phosphatidylcholine Transfer Protein Inhibitors - This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity. | 10-18-2012 |
20120263765 | AGENTS FROM CELLS - A composition includes an isolated cell; at least one particle within said cell; and at least one active agent associated with the particle, wherein the active agent is capable of being released from the cell. A method includes administration of such a cell to a subject. | 10-18-2012 |
20120263752 | Herpes Simplex Virus Vaccines - The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes. | 10-18-2012 |
20120251999 | VITRIFICATION SYSTEMS AND METHODS - The embodiments of the invention described herein relate to systems and methods for the vitrification of biological samples. Vitrification is achieved by generating nanodroplets of a solution comprising the biological sample with a means that can be automated and adapted to high-throughput applications. | 10-04-2012 |
20120251443 | IMPLANTABLE CONTRAST AGENTS AND METHODS - The present disclosure provides compositions and methods based on implantable contrast agents that are useful for imaging tissue and organs. | 10-04-2012 |
20120237488 | LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis. | 09-20-2012 |
20120230966 | TISSUE TRANSPLANT COMPOSITIONS AND METHODS FOR USE - Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ELA cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ELA stem cells or combination of ELA stem cells. | 09-13-2012 |
20120215223 | Medical Devices for Use During Ankle Fusion Surgery - The present invention is directed to devices and methods that can be used in ankle surgery, especially ankle fusion surgery. | 08-23-2012 |
20120208270 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-16-2012 |
20120208204 | Compositions and Methods for Inhibiting Tumor Growth - The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells. | 08-16-2012 |
20120202888 | BIOMARKERS OF PROSTATE CANCER AND PREDICTING MORTALITY - Measurement of circulating C-peptide levels is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of fatal prostate cancer. | 08-09-2012 |
20120202870 | TREATMENT OF INFLAMMATORY DISEASES USING MIR-124 - Methods of treating, reducing the risk of developing, or delaying the onset of an inflammatory disease are disclosed. The methods involved providing a subject with or at risk of developing an inflammatory disease and administering to the subject an effective amount of a first therapeutic composition comprising miR-124. Further provided are methods of diagnosing a subject with or at risk of developing an inflammatory disease. | 08-09-2012 |
20120202843 | H3K27me3 and Cancer - Methods of diagnosing and monitoring cancers and precancerous lesions associated with human papillomavirus (HPV), by detecting abnormal levels of lysine (K)-specific demethylase 6A (KDM6A), KDM6B, or trimethylated Histone H3 Lys27 (H3K27me3). | 08-09-2012 |
20120201834 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-09-2012 |
20120201833 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-09-2012 |
20120196359 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-02-2012 |
20120190106 | Promoter System for Regulatable Gene Expression in Mammalian Cells - The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way. | 07-26-2012 |
20120189571 | NANOSCALE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention. | 07-26-2012 |
20120171205 | Galectin-Immunoglobulin Chimeric Molecules - Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers. | 07-05-2012 |
20120149702 | INHIBITORS OF CELLULAR NECROSIS - The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis. | 06-14-2012 |
20120141470 | T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF - The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided. | 06-07-2012 |
20120128697 | NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 05-24-2012 |
20120107365 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 05-03-2012 |
20120101042 | Agents and Methods for Tissue Repair and Regeneration - Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described. | 04-26-2012 |
20120089030 | SYSTEM AND METHOD FOR CHARACTERIZATION OF ORAL, SYSTEMIC AND MUCOSAL TISSUE UTILIZING RAMAN SPECTROSCOPY - A method and system for characterizing tissue includes a probe connected to a red LASER source and a Raman spectroscope. The probe includes at least excitation fiber and one or more emission fibers that connect the probe with the LASER source and the Raman spectroscope. The excitation fiber is connected to the red LASER source and terminates in the first end of the probe adjacent the tip of the probe. The emission fibers are connected to the Raman spectroscope and terminate in the first end of the probe adjacent the tip of the probe. In one embodiment, the excitation fiber extends through the central portion of the probe and one or more emission fibers are arranged around the excitation fiber. The tip of the probe is intended to come in contact with the tissue to be examined. The tip includes a central opening to allow red LASER radiation to project out of the end of the red excitation fiber on to the tissue and to permit Raman spectra to enter the emission fiber(s) and travel to the Raman spectroscope. The tip is constructed to have a predefined focal length to position the first end of the probe a predefined distance from the surface of the tissue being examined. The tip can be removable and tips having different focal lengths can be used to accommodate different types of tissues and examinations. A detector can convert the Raman spectra into signals and data for analysis by a computer system. The Raman spectra for tissue in a predefined location can be profiled such that the system can distinguish between healthy and diseased tissue. | 04-12-2012 |
20120080592 | METHOD AND SYSTEM FOR SURFACE SAMPLING - A system and sampling probe adaptable to an ultrasonic surgical instrument applies irrigation fluid and ultrasonic or vibrational energy to a target, and aspirates material desorbed from the target into a pick-up conduit. A suction source at the distal end of the conduit may aspirate the material released from the target with the irrigation fluid, thus efficiently sampling a broad range of materials from an arbitrary target to produce an analyzable effluent analyte stream which may be ionized and provided to the inlet of an ion-type analysis instrument, or may be fed directly to an instrument such as a flow cytometer, IR or fluorescence spectrophotometer, or other analyzer. Carrier gas may be provided to more effectively transport the desorbed material, and the probe may be incorporated into a robotic device to automatically carry out surface imaging or to effect sampling in hazardous environments. | 04-05-2012 |
20120077770 | Methods of Diagnosing and Treating Multiple Sclerosis - Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARP-1). | 03-29-2012 |
20120077686 | DIAGNOSIS OF MULTIPLE SCLEROSIS - The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion. | 03-29-2012 |
20120076805 | Methods and Compositions for the Generation and Maintenance of Regulatory T Cells - Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided. | 03-29-2012 |
20120064108 | GLYCOCONJUGATE VACCINES - Glycoconjugate vaccines and methods of preparing and using the same are described. | 03-15-2012 |
20120040900 | COMPOSITIONS OF AND METHODS OF USING LIGAND DIMERS - Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment. | 02-16-2012 |
20120034196 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK) - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 02-09-2012 |
20120003737 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided. | 01-05-2012 |
20110301239 | USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 12-08-2011 |
20110300570 | METHOD AND SYSTEM FOR GENERATING SPATIALLY AND TEMPORALLY CONTROLLABLE CONCENTRATION GRADIENTS - The ability to rapidly generate concentration gradients of diffusible molecules has important applications in many chemical and biological studies. The present invention is directed to methods and systems for generating spatially and temporally controllable concentration gradients of molecules (i.e. proteins or toxins) in a portable microfluidic device. The formation of the concentration gradients can be initiated by an induced forward flow and further optimized during an induced backward flow. The forward and backward flows can be either passively induced and/or actively pumped. The centimeter-length gradients along the microfluidic channel can be spatially and temporally controlled by the backward flow. The gradient profile was stabilized by stopping the flow. In one example, a stabilized concentration gradient of a cardiac toxin, Alpha-cypermethrin, generated according to the invention was used to test the response of HL-1 cardiac cells in the microfluidic device, which correlated with toxicity data obtained from multi-well plates. The invention can be useful for bio-logical and chemical processes that require rapid generation of concentration gradients in a portable microfluidic device. | 12-08-2011 |
20110300219 | NANOSTRUCTURES FOR DRUG DELIVERY - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor. | 12-08-2011 |
20110287034 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS - Genes that are deregulated in cancer stem cells (e.g., melanoma stem cells) are disclosed. Methods which involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes are used to treat individuals having melanoma. Cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. | 11-24-2011 |
20110274703 | DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis. | 11-10-2011 |
20110274700 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as | 11-10-2011 |
20110269685 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 11-03-2011 |
20110268804 | TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. | 11-03-2011 |
20110245107 | SELECTIVE DIFFERENTIATION, IDENTIFICATION, AMD MODULATION OF HUMAN TH17 CELLS - The embodiments provide for the modulation of both the differentiation and activity of human TH17 cells. More specifically, human TH17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of TH17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of TH17 cells. More specifically, human TH17 cells specifically upregulate BLT1 and podoplanin. | 10-06-2011 |
20110213012 | Treatment of Cancers Characterized by Chromosomal Rearrangement of the NUT Gene - The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds. | 09-01-2011 |
20110212501 | 3-DIMENSIONAL MULTI-LAYERED HYDROGELS AND METHODS OF MAKING THE SAME - Embodiments of the invention provide three dimensional multi-layered hydrogel constructs with embedded channels, living cells and bioactive agents, and methods for making three dimensional multi-layered hydrogel constructs. The constructs can have bioactive agents to support the living cells. The multi-layered constructs can have channels for perfusion purposes and layers of different hydrogel materials. | 09-01-2011 |
20110206667 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT - This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid. | 08-25-2011 |
20110192974 | Preparation of Test Plates for Matrix Assisted Laser Desorption Ionization - The present invention is directed, sample test plates that can be used in matrix assisted laser desorption ionization. These plates have an etched surface and a layer of MALDI matrix material. The invention also includes methods for making these sample test plates and to methods for using the plates in the MS imaging of cell and tissue samples. | 08-11-2011 |
20110189151 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 08-04-2011 |
20110172785 | COMPLIANT COMPOSITES FOR APPLICATION OF DRUG-ELUTING COATINGS TO TISSUE SURFACES - A compliant composite for delivering a bioactive agent including a scaffolding material and a polymer coating that together can be attached to compliant tissue surfaces is disclosed, along with methods for constructing and applying these composites. In some embodiments, the composite further comprises a barrier layer for localized delivery of the bioactive agent. | 07-14-2011 |
20110171210 | HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells. | 07-14-2011 |
20110168177 | Anesthesia Simulator and Controller for Closed-Loop Anesthesia - Methods, systems, and software are disclosed for simulating and controlling anesthesia delivery and for implementing automatic closed-loop anesthesia with an inhaled anesthetic agent. The methods involve using a physiological simulation to forward calculate the effects of an inhaled anesthetic agent, and searching for gas administration characteristics, such as fresh gas flow rates and anesthetic concentrations or partial pressures, that will achieve a desired physiological anesthetic concentration or effect with minimal use of anesthetic agent and minimal fresh gas flow rate. | 07-14-2011 |
20110165149 | TARGETING ABCB5 FOR CANCER THERAPY - The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 07-07-2011 |
20110152305 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 06-23-2011 |
20110152249 | EVALUATING CENTRAL NERVOUS SYSTEM - Evaluating hemodynamic parameters in the cortex can be used as an objective test for CNS activity, e.g., pain. | 06-23-2011 |